On Wednesday, we’ll get to see earnings out of Biogen Idec Inc. (NASDAQ: BIIB). The estimates from First Call for the biotech company are $0.80 EPS on $835.16 million in ... Read Full Story »
Today was a brutal day for risk stocks, and biotechs are often thought of as risky to stocks as Russian Roulette is to your head. But Biotechs are also a ... Read Full Story »
Below is a snapshot of the key pre-market news that we are focusing on for early pre-market trading this Tuesday:Apple (AAPL) has its Macworld today.CECO Environmental (CECE) announced 14 new ... Read Full Story »
According to Reuters, the National Retail Federation and its members are preparing for a slow year.Reuters writes that the FCC has cleared Google (GOOG) to bid in the upcoming auction ... Read Full Story »
Genentech (NYSE: DNA) just announced its earnings were $0.69 EPS on $2.96 billion for the last quarter, and First Call had estimates pegged at $0.67 EPS on revenues of $2.97 ... Read Full Story »
Genentech (NYSE: DNA) is set to report earnings after the close today. First Call has estimates pegged at $0.67 EPS on revenues of $2.97 Billion. This will also mark the ... Read Full Story »
Rite Aid Corporation (RAD) Ugly earnings. No turnaround here. Falls to $2.71 from 52-week high of $6.74.MBIA (MBI) Concerns about CDOs being insured here. Falls to $18.84 from 52-week high ... Read Full Story »
These aren't the only analyst calls we are watching, but these are the top ten that 247WallSt.com is reviewing:AIG (AIG) reiterated Buy at Goldman Sachs.Apple (AAPL) target raised to $249 ... Read Full Story »
According to Reuters, Nikon is seeing a sharp increase in demand from LCD makers.Reuters writes that the housing slump will last through 2009 and some home prices will drop 30%. ... Read Full Story »
MBIA (MBI) Downgrade by Moody's. Falls to $25.84 from 52-week high of $76.02.Genentech (DNA) FDA rejects key drug. Drops to $65.54 from 52-week high of $89.73. AMD (AMD) More analyst ... Read Full Story »
According to the WSJ and other source, the FDA has rejected Genetech's (DNA) drug Avastin as a breast cancer treatment. Shares are off 9% on the newsDouglas A. McIntyre ... Read Full Story »
According to Reuters, the Henry Paulson said that a plan would be ready this week to spare some homeowners from mortgage resets.Reuters writes that November auto sales were weak with ... Read Full Story »
It might not be fair to only break out 10 analyst calls from the myriad of calls out there, because there are dozens to hundreds of changes daily. Here are ... Read Full Story »
According to Reuters, China CITIC Bank is bidding to buy a stake in Bear Stearns (BSC) Reuters reports that the National Retail Federation's survey of its members shows retail sales ... Read Full Story »
Genentech (NYSE:DNA) posted $0.73 EPS vs $0.72 estimates, but revenues were $2.95 Billion versus a $2.93 Billion estimate. It looks like 3 of the 4 major drugs came in under ... Read Full Story »